HRS-2329
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 07, 2026
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
(clinicaltrials.gov)
- P1 | N=120 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor • RAS
1 to 1
Of
1
Go to page
1